STING and ENPP1 programs in-licenced from CTxT

MELBOURNE — (June 30, 2020) — Aculeus Therapeutics has secured a world-wide exclusive licence to develop and commercialise small molecules that target STING and ENPP1. Both programs aim to discover and develop novel candidate drugs that activate the immune system and have therapeutic utility in treating a range of diseases including cancer.

The licence was signed between Aculeus Therapeutics and Cancer Therapeutics CRC (CTxT), a small molecule oncology drug discovery and development group that initiated the STING and ENPP1 programs. Aculeus Therapeutics CEO (Mark Devlin) and Head of Chemistry (Ben Morrow) both led research on these programs at CTxT and are now progressing them at Aculeus.